Scientist, Founder of IPQ Analytics

Dr. Michael Liebman

Meet Dr. Michael Liebman

Michael N. Liebman, Ph.D (theoretical chemistry and protein crystallography) is the Managing Director of IPQ Analytics, LLC and Strategic Medicine, Inc after serving as the Executive Director of the Windber Research Institute (now Chan Soon-Shiong Institute for Molecular Medicine) from 2003-2007. He is an Adjunct Professor of Pharmacology and Physiology at Drexel College of Medicine, Research Professor of Biology at University of Massachusetts-Lowell and Adjunct Professor of Drug Discovery, First Hospital of Wenzhou Medical University and also Fudan University. He serves on the Advisory Board for the International Park for Translational Biomedicine (Shanghai) and the Center of Biomedical and Health Research in Data Sciences, Univ Massachusetts(Lowell). Previously, he was Director, Computational Biology and Biomedical Informatics, University of Pennsylvania Cancer Center 2000-2003. He served as Global Head of Computational Genomics, Roche Pharmaceuticals and Director, Bioinformatics and Pharmacogenomics, Wyeth Pharmaceuticals, Director of Genomics for Vysis, Inc. He is a co-founder of Prosanos, Inc (now United BioSource) (2000). He was Associate Professor of. Pharmacology and of Physiology/Biophysics at Mount Sinai School of Medicine. He serves on 14 scientific advisory boards and is an advisor in digital health and quantum computing and serves on the Board of Directors of the Nathaniel Adamczyk Foundation in Pediatric ARDS. Michael is Chair of the Informatics Program and also Chair of Translational Medicine and Therapeutics for the PhRMA Foundation and a member of their Scientific Advisory Board. He is on the Advisory Board of the International Society for Translational Medicine and on the Editorial Board for the Journal of Translational Medicine, for Clinical and Translational Medicine and for Molecular Medicine and Therapeutics, for Clinico-Economics and Outcomes Research, Exploratory Research and Hypothesis in Medicine and Biomedicine Hub. He is a member of the IUPAC Division on Human Health’s Medicinal Chemistry subcommittee. He has served on the External Advisory Board for the INBRE (NIH) program for the state of Delaware since 2000. He is an Invited Professor at the Shanghai Center for Bioinformatics Technology and of the Chinese Academy of Sciences. He is Project Leader for the Institute for Human Centered Health Innovation, co-lead of the EU IHI Learning CVD consortium and CSO for the United Cancer Center Network. His research focuses on computational models of disease progression that stress risk detection, disease processes and clinical pathway modeling, and disease stratification from the clinical perspective. He utilizes systems-based approaches and design thinking to represent and analyze risk/benefit analysis in pharmaceutical development and healthcare and reimbursement. Current application areas include: multiple sclerosis, heart failure, triple negative breast cancer, hypertension and hypertensive disorders of pregnancy, infant-maternal morbidity and mortality, perimenopause-menopause transition with an emphasis on underserved populations and health disparities.

PRETTY MOODY x IPQ ANALYTICS - WHAT ARE WE DOING?

Pretty Moody Foundation (Delaware), in collaboration with IPQ Analytics, LLC (Pennsylvania), is launching a menopause study to help better understand & define how women progress through peri-menopause &
menopause to provide critical insights to support the smooth, natural transition. In the United States, approximately 50% of all women are age 40 or older, with the average
start of peri-menopause at 40 and menopause at 50 years of age. By the
year 2025, it is said that approximately 1.1 billion women would have entered into menopause. Thus, while a woman lives approximately half of her life in menopause after its’ start, the transition is poorly understood by clinicians and women themselves, especially as each woman’s menopause journey is different. It is noted that only 31.3% of OBGYN residency programs have a menopause curriculum as part of their residency training program, leaving women, healthcare providers, and researchers without the educational resources they need. Although hot flashes are among the most visible and recognizable symptoms of menopause, cardiovascular disease, osteoporosis, mental health disorders, and disordered sleep are other common and debilitating symptoms. These treatable conditions affect daily functioning and costs $1.8 billion dollars annually in
lost work productivity. Given the significance and scope, it is past time to advance policies that improve menopause research and awareness.